Michael Bretherton

Mr. Michael A. Bretherton is a Chairman at Hardy Plc, an Independent Non-Executive Director at Tangram Therapeutics Plc, a Chairman at Adams Plc, a Chief Executive Officer & Executive Director at Sarossa Plc and a Member at The Institute of Chartered Accountants in England & Wales.
He is on the Board of Directors at Tangram Therapeutics Plc, Sarossa Plc, Blake Holdings Ltd., Blake Holdings Ltd. (Jersey) and ORA Capital Partners Ltd. Mr. Bretherton was previously employed as a Finance Director, Secretary & Director by DeepMatter Group Plc, a Non-Executive Director by Ceres Power Holdings plc, a Chief Executive Officer by Sarossa Capital Ltd., a Non-Executive Director by Tissue Regenix Group Plc, a Non-Executive Director by Nanoco Group Plc, a Finance Director by ORA Capital Partners Ltd., a Finance Director by Bridgend Group Plc, a Manager-Corporate Finance by The Plessey Co. Plc, an Executive Director & Finance Director by Oxford Pharmascience Group Plc, a Director & Partner by Abway Enterprises Corp., an Independent Non-Executive Director by DeepMatter Group Plc, a Director-Financial Operations by Mapeley Estates Ltd., a Director & Partner by Nanoco Technologies Ltd., a Director & Partner by Ora Capital Services Ltd., an Executive Chairman & Finance Director by Oxeco Plc, a Director & Partner by Oxray Ltd., a Manager & Accountant by PricewaterhouseCoopers LLP (United Kingdom), and a Director & Finance Director by Obtala Ltd. He also served on the board at Oxford Pharmascience Ltd., OBTALA SERVICES LTD, AlbR Capital Ltd., Kanyon Plc, Novum Nominees Ltd., Novum Private Clients Ltd., ORA Ltd. and Oxford Nutra Ltd. He received his undergraduate degree from the University of Leeds.